PTC Therapeutics price target raised to $43 from $34 at Roth Capital Roth Capital increased its price target on PTC as the firm thinks that, based on recent favorable developments, the company's spinal muscular atrophy program is gaining steam. Roth believes that the compounds identified by PTC can be expanded to other neuro-muscular disorders. Roth reiterates a Buy rating on the stock.
JPMorgan upgrades PTC Therapeutics with $100 target ahead of data JPMorgan analyst Anupam Rama upgraded PTC Therapeutics (PTCT) to Overweight from Neutral citing an attractive risk/reward profile into the phase 3 results for Translarna in non-sense mutation Duchenne Muscular Dystrophy. The data are expected in Q4. Rama believes the study is designed for success and raised the firm's probability of success to 80%. PTC shares are off down 37% since the mid-March highs when takeout speculation was a key driver of appreciation, Rama tells investors this morning in a research note. The analyst raised PTC's price target to $100 from $74. Shares of PTC closed yesterday up $1.30 to $48.94.